Loading...
XPARBIM
Market cap12bUSD
Dec 20, Last price  
102.20EUR
1D
0.89%
1Q
-3.95%
Jan 2017
116.07%
Name

Biomerieux SA

Chart & Performance

D1W1MN
XPAR:BIM chart
P/E
33.70
P/S
3.28
EPS
3.03
Div Yield, %
0.83%
Shrs. gr., 5y
0.07%
Rev. gr., 5y
8.70%
Revenues
3.67b
+2.38%
993,600,0001,036,900,0001,062,800,0001,110,500,0001,223,400,0001,357,000,0001,427,200,0001,569,800,0001,587,900,0001,698,400,0001,964,600,0002,103,199,9992,288,200,0002,421,300,0002,674,800,0003,118,200,0003,376,200,0003,589,100,0003,674,700,000
Net income
358m
-20.95%
90,100,000105,300,00098,100,000130,000,000148,200,000160,000,000160,500,000134,400,000164,300,000134,900,000110,500,000179,100,000238,100,000256,600,000272,800,000404,400,000601,100,000452,400,000357,600,000
CFO
445m
-6.25%
164,500,000124,600,000188,700,000197,900,000188,600,000199,000,000216,600,000258,500,000240,500,000298,300,000310,000,000335,600,000341,300,000399,800,000407,900,000582,800,000824,700,000475,100,000445,400,000
Dividend
Jun 07, 20240.85 EUR/sh
Earnings
Mar 12, 2025

Profile

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
URL
https://www.biomerieux.fr/
IPO date
Jun 07, 2004
Employees
12,557
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,674,700
2.38%
3,589,100
6.31%
3,376,200
8.27%
Cost of revenue
3,098,000
3,029,300
2,608,200
Unusual Expense (Income)
NOPBT
576,700
559,800
768,000
NOPBT Margin
15.69%
15.60%
22.75%
Operating Taxes
114,500
109,700
149,400
Tax Rate
19.85%
19.60%
19.45%
NOPAT
462,200
450,100
618,600
Net income
357,600
-20.95%
452,400
-24.74%
601,100
48.64%
Dividends
(100,200)
(101,200)
(73,100)
Dividend yield
0.84%
0.87%
0.49%
Proceeds from repurchase of equity
12,700
(14,200)
50,100
BB yield
-0.11%
0.12%
-0.34%
Debt
Debt current
163,400
187,000
99,700
Long-term debt
503,900
318,400
362,800
Deferred revenue
300
93,700
97,600
Other long-term liabilities
53,300
41,200
62,500
Net debt
94,700
(138,200)
(403,000)
Cash flow
Cash from operating activities
445,400
475,100
824,700
CAPEX
(338,300)
(286,700)
(290,100)
Cash from investing activities
(488,800)
(528,100)
(307,300)
Cash from financing activities
(122,300)
(244,200)
(140,600)
FCF
64,400
110,000
414,900
Balance
Cash
352,400
552,600
803,500
Long term investments
220,200
91,000
62,000
Excess cash
388,865
464,145
696,690
Stockholders' equity
369,600
4,057,300
3,711,300
Invested Capital
3,954,600
3,676,355
2,924,510
ROIC
12.11%
13.64%
22.00%
ROCE
13.30%
13.35%
20.86%
EV
Common stock shares outstanding
118,802
118,441
118,893
Price
100.60
2.74%
97.92
-21.60%
124.90
8.23%
Market cap
11,951,528
3.05%
11,597,703
-21.90%
14,849,772
8.45%
EV
12,046,228
11,498,203
14,498,172
EBITDA
835,600
817,400
988,400
EV/EBITDA
14.42
14.07
14.67
Interest
4,400
4,100
9,100
Interest/NOPBT
0.76%
0.73%
1.18%